Company
Headquarters: Gothenburg, Sweden
Employees: 1,171
CEO: Mr. Thomas Axelsson M.Sc.
kr23.03 Billion
SEK as of July 1, 2024
US$2.17 Billion
Company | Market Cap (USD) |
---|---|
Abbott | $178.02 B |
Stryker Corporation | $126.48 B |
Boston Scientific Corporation | $112.32 B |
Medtronic | $98.95 B |
Edwards Lifesciences Corporation | $55.63 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Vitrolife AB has the following listings and related stock indices.
Stock: OMX: VITR wb_incandescent
Stock: FSX: VTFN wb_incandescent